Researchers at the Ludwig-Maximilians-University, the German Center for Neurodegenerative Diseases (DZNE), and the Institute for Stroke and Dementia Research (ISD) in Munich, Germany, have identified a brain inflammation marker in patients at early asymptomatic stages of Alzheimer’s disease. This secreted marker molecule may provide clinicians with a rapidly detectable biomarker for the transition from preclinical Alzheimer’s disease to cognitive impairment and progression to full dementia. Such is the conclusion of a multi-center study on a large group of human patients, published online in EMBO Molecular Medicine.
Alzheimer’s disease, an increasing problem in today’s aging populations, is characterized by amyloid peptide plaques and tau protein aggregates in nerve cells. Understanding its molecular causes and risk factors has been challenging because most cases develop sporadically without inherited genetic mutations, and because of the gradual progression of symptoms over the course of disease.
Recognizing affected individuals early would be important for increasing treatment options and facilitating clinical trials of new therapeutics. However, the currently available preclinical diagnostics based on amyloid peptide and tau protein forms in the cerebrospinal fluid are not sufficiently specific, as individuals exhibiting them may still retain normal cognitive capabilities for years before developing dementia.
In the present work, the teams led by Michael Ewers (ISD) and EMBO Member Christian Haass (DZNE) focussed on the TREM2 protein, which functions in specialized brain immune cells called microglia that clear toxic material resulting from nerve cell injury. Microglia are activated during Alzheimer’s disease progression and may mediate an initially protective inflammatory response, a notion that is also supported by epidemiological studies linking mutations in the TREM2 gene to increased risk of Alzheimer’s and other neurodegenerative diseases.
Conducting a cross-sectional study of a large cohort of patients with different levels of cognitive impairment and different disease stages, the researchers found that the amounts of a TREM2 fragment in the cerebrospinal fluid were highest during early stages characterized by mild cognitive impairment symptoms.
Its levels declined again in late-stage patients with full dementia, closely mirroring the pattern of microglia activity during the course of the disease. Together, these findings indicate that microglia-mediated brain inflammation may demarcate the transition from preclinical Alzheimer’s disease to full dementia.
“We now have the first marker for the capacity of brain immune cells to remove toxic materials,” says Haass, “and its increase long before full Alzheimer’s dementia shows that there is early neuronal injury that does not yet affect memory, but already triggers a microglia response.” And Ewers adds, “If this response is indeed protective, then therapeutically modulating the activity of microglia could be beneficial in late-stage Alzheimer’s patients as well as other brain disorders.”
Read the article:
sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer’s Disease and associate with neuronal injury markers
Suárez-Calvet M, Kleinberger G, Caballero MA, Brendel M, Rominger A, Alcolea D, Fortea J, Lleó A, Blesa R, Gispert JD, Sánchez-Valle R, Antonell A, Rami L, Molinuevo JL, Brosseron F, Traschütz A, Heneka MT, Struyfs H, Engelborghs S, Sleegers K, Van Broeckhoven C, Zetterberg H, Nellgård B, Blennow K, Crispin A, Ewers M, Haass C
Yvonne Kaul | idw - Informationsdienst Wissenschaft
How molecules teeter in a laser field
18.01.2019 | Forschungsverbund Berlin
Discovery of enhanced bone growth could lead to new treatments for osteoporosis
18.01.2019 | University of California - Los Angeles
The scientific and political community alike stress the importance of German Antarctic research
Joint Press Release from the BMBF and AWI
The Antarctic is a frigid continent south of the Antarctic Circle, where researchers are the only inhabitants. Despite the hostile conditions, here the Alfred...
World first experiments on sensor that may revolutionise everything from medical devices to unmanned vehicles
The new sensor - capable of detecting vibrations of living cells - may revolutionise everything from medical devices to unmanned vehicles.
Dead and alive at the same time? Researchers at the Max Planck Institute of Quantum Optics have implemented Erwin Schrödinger’s paradoxical gedanken experiment employing an entangled atom-light state.
In 1935 Erwin Schrödinger formulated a thought experiment designed to capture the paradoxical nature of quantum physics. The crucial element of this gedanken...
Cellulose obtained from wood has amazing material properties. Empa researchers are now equipping the biodegradable material with additional functionalities to produce implants for cartilage diseases using 3D printing.
It all starts with an ear. Empa researcher Michael Hausmann removes the object shaped like a human ear from the 3D printer and explains:
The phenomenon of so-called superlubricity is known, but so far the explanation at the atomic level has been missing: for example, how does extremely low friction occur in bearings? Researchers from the Fraunhofer Institutes IWM and IWS jointly deciphered a universal mechanism of superlubricity for certain diamond-like carbon layers in combination with organic lubricants. Based on this knowledge, it is now possible to formulate design rules for supra lubricating layer-lubricant combinations. The results are presented in an article in Nature Communications, volume 10.
One of the most important prerequisites for sustainable and environmentally friendly mobility is minimizing friction. Research and industry have been dedicated...
16.01.2019 | Event News
14.01.2019 | Event News
12.12.2018 | Event News
18.01.2019 | Materials Sciences
18.01.2019 | Life Sciences
18.01.2019 | Health and Medicine